Targeting high mobility group box protein 1 ameliorates testicular inflammation in experimental autoimmune orchitis

被引:42
|
作者
Aslani, Ferial [1 ]
Schuppe, Hans-Christian [2 ]
Guazzone, Vanesa A. [3 ]
Bhushan, Sudhanshu [1 ]
Wahle, Eva [1 ]
Lochnit, Guenter [4 ]
Lustig, Livia [3 ]
Meinhardt, Andreas [1 ]
Fijak, Monika [1 ]
机构
[1] Univ Giessen, Dept Anat & Cell Biol, D-35392 Giessen, Germany
[2] Univ Giessen, Dept Urol Pediat Urol & Androl, D-35392 Giessen, Germany
[3] Univ Buenos Aires, Fac Med, Inst Invest Biomed UBA CONICET, Buenos Aires, DF, Argentina
[4] Univ Giessen, Inst Biochem, Fac Med, D-35392 Giessen, Germany
关键词
testicular inflammation; experimental autoimmune orchitis; high mobility group box protein-1; receptor for advanced glycation end products; ethyl pyruvate; GLYCATION END-PRODUCTS; ETHYL PYRUVATE; RAT TESTIS; SIGNALING PATHWAYS; IMMUNE PRIVILEGE; GENE-EXPRESSION; LETHAL SEPSIS; SERTOLI-CELLS; HMGB1; RELEASE; RECEPTOR;
D O I
10.1093/humrep/deu320
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
STUDY QUESTION: Does high mobility group box protein 1 (HMGB1) regulate inflammatory reactions in a rat model of experimental autoimmune orchitis (EAO)? SUMMARY ANSWER: HMGB1 appears to be involved in regulating inflammatory reactions in testes, as HMGB1 is translocated from testicular cells during the course of EAO and blocking its action by ethyl pyruvate (EP) reduces disease progression and spermatogenic damage. WHAT IS KNOWN ALREADY: Despite its immune privileged status, the human testis is prone to inflammatory lesions associated with male factor infertility. Accumulating evidence shows that HMGB1 plays an important role in onset and progression of autoimmune diseases. STUDY DESIGN, SIZE, DURATION: This is a cross sectional and longitudinal study involving Wistar male rats immunized with testicular homogenates to induce EAO50 (EAO50; n = 10) and 80 (EAO80; n = 10) days after first immunization. Control adjuvant animals received saline instead of testicular homogenate (n = 16). Untreated animals (n = 10) were also studied. An interventional study was performed to block the action of HMGB1 starting 20 days after first immunization in EAO animals and respective controls (n = 17). Ratswere treated i.p. with EP and the effect of EP treatment on testicular pathogenesis was evaluated 30 days later. Moreover, human testicular biopsies from infertile men with focal lymphocytic infiltrates (n = 7) and sections with intact spermatogenesis (n = 6) were probed with antibodies against HMGB1. PARTICIPANTS/MATERIALS, SETTING, METHODS: Testicular RNA and protein extracts from EAO animals, EAO animals treated with EP and relevant controls were used for analysis of cytokine expression by real-time RT-PCR and enzyme-linked immunosorbent assay. HMGB1 was co-localized on rat testicular cross sections with antibodies against testicular macrophages (TM), peritubular cells (PTC) and Sertoli cells (SC). Interaction of HMGB1 and its receptors (RAGE, TLR4) as well signaling pathways after HMGB1 stimulation were studied in isolated TM, PTC and SC by proximity ligation assay and western blot, respectively. Furthermore, HMGB1 immunofluorescence on human testicular biopsies was performed. MAIN RESULTS AND THE ROLE OF CHANCE: HMGB1 was translocated from the nuclei in EAO testes and testes of infertile men with impaired spermatogenesis and lymphocytic infiltrates. Elevated HMGB1 levels were observed during late phase of EAO. In testicular somatic cells HMGB1 receptors Toll-like receptor 4 (TLR4) and receptor for advanced glycation end products (RAGE) were differentially expressed: HMGB1-TLR4 binding was predominant in TM, while HMGB1-RAGE interaction was prevalent in SC and PTC. In support, HMGB1 triggered extracellular signal regulated kinase (ERK) 1/2 and cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) activation in SC and PTC, while TM responded to HMGB1 stimulation with p38 mitogen-activated protein kinase (MAPK) and p65 nuclear factor Kappa B (NF-kappa B) phosphorylation followed by increased tumor necrosis factor a (TNF-alpha) and interleukin 6 (IL-6) mRNA levels. In vivo treatment of EAO animals with EP 20 days after induction of disease revealed beneficial effects, as documented by reduced disease progression and spermatogenic damage, lower macrophage numbers, as well as decreased concentrations of HMGB1 and IL-6 in the testis compared with EAO controls. LIMITATIONS, REASONS FOR CAUTION: The ability of HMGB1 to bind to a wide range of receptors makes it difficult to prevent its action by blockade of a specific receptor; therefore we applied EP, a drug preventing HMGB1 release from cells. Due to its mode of action EP decreases also the secretion of some other pro-inflammatory cytokines. Using isolated primary cells imposes limitations for cell transfection studies. As a compromise between purity and yield primary cells need to be isolated from animals of different age, which has to be considered when comparing their responses. WIDER IMPLICATIONS OF THE FINDINGS: HMGB1 could be a promising target in attenuating testicular damage caused by inflammatory reactions.
引用
收藏
页码:417 / 431
页数:15
相关论文
共 50 条
  • [1] High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis
    Robinson, Andrew P.
    Caldis, Matthew W.
    Harp, Christopher T.
    Goings, Gwendolyn E.
    Miller, Stephen D.
    JOURNAL OF AUTOIMMUNITY, 2013, 43 : 32 - 43
  • [2] High Mobility Group Box Protein-1 in Experimental Autoimmune Uveoretinitis
    Watanabe, Takayo
    Keino, Hiroshi
    Sato, Yasuhiko
    Kudo, Akihiko
    Kawakami, Hayato
    Okada, Annabelle A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2009, 50 (05) : 2283 - 2290
  • [3] Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis
    Uzawa, A.
    Mori, M.
    Taniguchi, J.
    Masuda, S.
    Muto, M.
    Kuwabara, S.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 172 (01): : 37 - 43
  • [4] Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines
    Uzawa, A.
    Mori, M.
    Masuda, H.
    Ohtani, R.
    Uchida, T.
    Kuwabara, S.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 193 (01): : 47 - 54
  • [5] Targeting high mobility group box 1 as a late-acting mediator of inflammation
    Czura, CJ
    Tracey, KJ
    CRITICAL CARE MEDICINE, 2003, 31 (01) : S46 - S50
  • [6] The role of high-mobility group box 1 protein in the pathogenesis of autoimmune diseases
    Reinhard E. Voll
    Vilma Urbonaviciute
    Barbara Fürnrohr
    Martin Herrmann
    Joachim R. Kalden
    Current Rheumatology Reports, 2008, 10 (5) : 341 - 342
  • [7] Rhinosinusal Inflammation and High Mobility Group Box 1 Protein: A New Target for Therapy
    Bellussi, Luisa Maria
    Cocca, Serena
    Chen, Lei
    Passali, Francesco Maria
    Sarafoleanu, Condrut
    Passali, Desiderio
    ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY, 2016, 78 (02): : 77 - 85
  • [8] High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases
    Voll, Reinhard E.
    Urbonaviciute, Vilma
    Herrmann, Martin
    Kalden, Joachim R.
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2008, 10 (01): : 26 - 28
  • [9] Protective Targeting of High Mobility Group Box Chromosomal Protein 1 in a Spontaneous Arthritis Model
    Ostberg, Therese
    Kawane, Kohki
    Nagata, Shigekazu
    Yang, Huan
    Chavan, Sangeeta
    Klevenvall, Lena
    Bianchi, Marco E.
    Harris, Helena Erlandsson
    Andersson, Ulf
    Palmblad, Karin
    ARTHRITIS AND RHEUMATISM, 2010, 62 (10): : 2963 - 2972
  • [10] High-mobility box group 1 protein: An alarmin driving dry eye inflammation?
    Lema, Carolina
    Reins, Rose Y.
    Zhang, Betty
    Redfern, Rachel L.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)